Idorsia Ltd. · SIX:IDIA

Idorsia — Technical Presentation (August 2020)

20 slides from Idorsia's technical presentation, Aug 28, 2020

  1. Slide 1: Efficacy and Safety of Daridorexant in Adult and Elderly Patients with Insomnia

    Efficacy and Safety of Daridorexant in Adult and Elderly Patients with Insomnia Dr Tom Roth Division of Sleep Medicine and Research Center, Henry Ford Health System, Detroit, USA

  2. Slide 2: Potential Conflict of Interest Disclosure

     Type of Potential Conflict Details of Potential Conflict Grant/Research Support n Consultant Eisai, Idorsia, jazz, Merck, Takeda, Philips, Novartis ,seq Speakers’ Bureaus Financial support Other  1. Consultancy agreement between the speaker and Idorsia Pharmaceuticals Ltd 2. 3.

  3. Slide 3: Rationale

    Rationale • Daridorexant, a new dual orexin receptor antagonist optimized for onset and duration of action at optimally effective doses, dose-dependently (5–50 mg) improved night- time efficacy, without residual effects, in adult and elderly patients with insomnia in phase 21,2 • These pharmacologic

  4. Slide 4: Objective

    Objective • This phase 3 trial was designed to measure the impact of daridorexant on objective and subjective sleep parameters as well as on daytime functioning, and to evaluate safety, in patients with moderate to severe insomnia o Sleep variables were assessed using PSG (WASO, LPS) and a sleep dia

  5. Slide 5: IDSIQ - Insomnia Daytime Symptoms and Impacts Questionnaire

    IDSIQ - Insomnia Daytime Symptoms and Impacts Questionnaire Patient-reported outcome instrument validated according to FDA guidance1 Measures • Items are ranked on a NRS scale from 0-10 1 Clear-Headed “Alert/cognition” 19:30 2 Concentrate domain score 3 Forgetful (0-60) 4 Worried 11. How mentally ti

  6. Slide 6: Study Design

    Study Design Phase 3, multi-center, double-blind, randomized, placebo-controlled, PSG study Screening 20-31days Treatment Period 84 days Safety Follow-up 30 days Nightly oral DB treatment with placebo or daridorexant 25 mg or 50 mg Daily assessment of sleep and daytime functioning EODBT 1st month 2n

  7. Slide 7: Endpoints

    Endpoints Primary efficacy • WASO • LPS Type I error rate (5%) was controlled across Secondary efficacy • sTST the primary and secondary endpoints assessed at Month 1 and Month 3 for each • IDSIQ sleepiness domain active dose (25 and 50 mg) comparison vs placebo (16 comparisons) Other efficacy • IDS

  8. Slide 8: Patient Disposition

    Patient Disposition Key entry criteria  Adults (18-64 yr) and elderly (≥65 yr)  History of sleep-related breathing disorder  Insomnia disorder (DSM-5)  History of suicidal ideation/attempt  ISI score ≥15  Acute/unstable psychiatric conditions (inc. 3326 screened  No other sleep disorder depre

  9. Slide 9: Patient Population

    Patient Population Daridorexant Daridorexant Placebo 25 mg 50 mg (N=310) (N=310) (N=310) Demographics Female Sex – % 68 69 64 Age – mean ±SD, years 55 ± 15 56 ± 15 56 ± 15 ≥65 – % 39 39 39 Race– % Black or African American 9 6 10 Asian 0 1 1 US region - % 34 32 31 Baseline sleep characteristics, mea

  10. Slide 10: Improvement in WASO

    Improvement in WASO Placebo Daridorexant 25 mg Daridorexant 50 mg Two-sided p-values are versus placebo and statistically significant under the control of type I error Mixed effects model for repeated measures adjusted for: baseline value, age group (< 65; ≥ 65 years), treatment, time point, interac

  11. Slide 11: Improvement in LPS

    Improvement in LPS Placebo Daridorexant 25 mg Daridorexant 50 mg Two-sided p-values are versus placebo and statistically significant under the control of type I error Mixed effects model for repeated measures adjusted for: baseline value, age group (< 65; ≥ 65 years), treatment, time point, interact

  12. Slide 12: Improvement in sTST

    Improvement in sTST Placebo Daridorexant 25 mg Daridorexant 50 mg Two-sided p-values are versus placebo and statistically significant under the control of type I error Mixed effects model for repeated measures adjusted for: baseline value, age group (< 65; ≥ 65 years), treatment, time point, interac

  13. Slide 13: Improvement in IDSIQ Sleepiness/Tiredness Domain Score

    Improvement in IDSIQ Sleepiness/Tiredness Domain Score Placebo Daridorexant 25 mg Daridorexant 50 mg Two-sided p-values are versus placebo and for 50 mg (but not 25 mg), are statistically significant under the control of type I error Mixed effects model for repeated measures adjusted for: baseline v

  14. Slide 14: Improvement in Daytime Function

    Improvement in Daytime Function IDSIQ total score, mood domain, and alert/cognition domain Total IDSIQ score Alert/cognition domain Mood domain Placebo Daridorexant 25 mg Daridorexant 50 mg Nominal two-sided p-values (versus placebo) are not under type 1 error rate control (not adjusted for multipli

  15. Slide 15: Overall Safety

    Overall Safety Adverse events Daridorexant Daridorexant Placebo 25 mg 50 mg No. of patients (%) (N=309) (N=310) (N=308) Patients with ≥1 adverse event 105 (34.0) 117 (37.7) 116 (37.7) Patients with a given adverse event (≥2% in any group) Nasopharyngitis 20 (6.5) 21 (6.8) 20 (6.5) Headache 12 (3.9)

  16. Slide 16: No evidence of Residual Sleepiness in the Morning

    No evidence of Residual Sleepiness in the Morning Mean values for VAS morning sleepiness were increased at months 1 and 3 Daridorexant Daridorexant Placebo 25 mg 50 mg VAS morning sleepiness (mm), mean ±SD (N=280) (N=286) (N=286) Baseline 37 ± 19 37 ± 19 38 ± 19 Change from baseline to Month 1 5 ± 1

  17. Slide 17: No evidence of Rebound Insomnia after Termination

    No evidence of Rebound Insomnia after Termination Mean values for WASO, LPS, and sTST at run-out were improved from baseline Daridorexant Daridorexant Placebo 25 mg 50 mg (minutes) mean ±SD (N=280) (N=286) (N=286) WASO Change from BL to run-out (V9*) -20.4 ± 45.8 -8.6 ± 55.5 -2.5 ± 52.4 LPS Change f

  18. Slide 18: No evidence of Withdrawal effects

    No evidence of Withdrawal effects • BWSQ scores (assessing potential withdrawal) were decreased in all treatment groups at each run-out assessment • No AEs suggestive of withdrawal were observed Daridorexant Daridorexant Placebo 25 mg 50 mg BWSQ score, mean ±SD (N=280) (N=286) (N=286) Last assessmen

  19. Slide 19: Summary

    Summary • Daridorexant improved daytime functioning at Month 1 and 3, as measured by reductions in IDSIQ total score and its constituent domains o Daridorexant 50 mg significantly improved sleepiness/tiredness domain scores using the new validated IDSIQ PRO tool, indicating patients felt less sleepy

  20. Slide 20: Acknowledgments

    Acknowledgments • The authors would like to thank: • All study investigators (75 sites across 10 countries) • IDMC members: A. Krystal, G.J. Lammers, K. Kim • ISB members: Y. Dauvilliers, G. Plazzi, T. Scammel • The participants, study staff, and nursing teams for their participation in this researc

Idorsia — Technical Presentation (August 2020) on 6ix